Does astaxanthin cause gynaecomastia? This is a question increasingly raised by men taking this popular marine-derived antioxidant supplement. Astaxanthin, a carotenoid pigment found in salmon, krill, and microalgae, is widely sold in the UK as an over-the-counter food supplement for purported antioxidant and anti-inflammatory benefits. Whilst some theoretical concerns exist around its potential influence on hormonal pathways, understanding what the current evidence actually shows — and when to seek medical advice about breast tissue changes — is essential for anyone considering or already using this supplement.

What Is Astaxanthin and How Is It Used in the UK?

Astaxanthin is a marine-derived carotenoid supplement authorised as a novel food in Great Britain, considered safe by EFSA at up to 8 mg/day for healthy adults, though no health claims are authorised by UK or EU regulators.

Astaxanthin is a naturally occurring carotenoid pigment — a type of antioxidant compound — found predominantly in marine organisms such as salmon, trout, krill, and microalgae, particularly Haematococcus pluvialis. It is responsible for the characteristic pink-red colouration seen in these species. In the UK, astaxanthin is widely available as an over-the-counter food supplement, typically sold in capsule or softgel form.

Regarding safety and dosing, the European Food Safety Authority (EFSA) has concluded that astaxanthin from Haematococcus pluvialis extract is safe for healthy adults at up to 8 mg per day. Lower limits apply for adolescents aged 14–18 years (around 4 mg per day), and there are insufficient data to establish safe intake levels during pregnancy or breastfeeding — women in these groups are therefore advised to avoid astaxanthin supplements. Some products available in the UK are sold at doses above 8 mg per day; consumers should be aware that these exceed the level considered safe by EFSA for the general adult population. In Great Britain, astaxanthin-rich oleoresin from Haematococcus pluvialis is authorised as a novel food by the Food Standards Agency (FSA), with conditions of use that reflect these population-specific restrictions.

Consumers and practitioners use astaxanthin for a variety of purported health benefits, including antioxidant support, anti-inflammatory effects, skin health, eye health, and sports performance. It is important to note that none of these uses has been granted an authorised health claim by EFSA or UK regulatory bodies, and the clinical evidence in humans remains limited and inconsistent. These should be regarded as marketing claims rather than established medical benefits. Mild gastrointestinal effects (such as nausea or loose stools) have been reported in some clinical trials, though these are generally uncommon at recommended doses.

As a food supplement rather than a licensed medicine, astaxanthin is not regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) in the same way as pharmaceutical products. Manufacturers are not required to conduct the same rigorous clinical trials needed for drug approval. Consumers in the UK should purchase supplements from reputable sources and be aware that quality and purity can vary considerably between brands.

Understanding Gynaecomastia: Causes and Risk Factors

Gynaecomastia is benign male breast glandular enlargement caused by an oestrogen-to-androgen imbalance; common causes include medications, recreational drugs, and medical conditions such as hypogonadism or liver cirrhosis.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, resulting from an imbalance between the effects of oestrogen and androgens (particularly testosterone) on breast tissue. It is a relatively common condition — affecting an estimated 30–60% of males at some point during their lifetime — and can occur at any age, though it is particularly prevalent during puberty and in older men.

The underlying mechanism typically involves either an increase in circulating oestrogen, a reduction in androgen activity, or an increase in the ratio of oestrogen to androgen at the tissue level. Common and well-established causes include:

• Physiological changes — puberty, ageing, and neonatal gynaecomastia

• Medications — including spironolactone, cimetidine, anabolic steroids, 5-alpha-reductase inhibitors (such as finasteride and dutasteride), antiandrogens, exogenous oestrogens, some antipsychotics, certain antihypertensives, and some antiretrovirals

• Recreational drugs and alcohol — cannabis, heroin, and excessive alcohol consumption

• Medical conditions — hypogonadism, hyperthyroidism, liver cirrhosis, chronic kidney disease, and testicular tumours

• Herbal and dietary supplements — some plant-based products with oestrogenic or anti-androgenic properties

NICE Clinical Knowledge Summaries (CKS) on gynaecomastia and standard clinical practice recommend a thorough history and examination when gynaecomastia is identified, including a detailed medication and supplement review. It is worth distinguishing true gynaecomastia (glandular tissue proliferation) from pseudogynaecomastia, which involves fatty tissue deposition without glandular involvement and is more closely associated with obesity. Accurate diagnosis is important, as the management approach differs significantly between these two presentations.

Any new or rapidly progressive breast tissue change in a male should be assessed promptly to exclude underlying pathology, including malignancy. NICE guidance (NG12: Suspected Cancer — Recognition and Referral) sets out urgent referral criteria for male breast symptoms; men aged 50 or over with a unilateral, firm subareolar mass, with or without nipple retraction or discharge, should be referred via the 2-week-wait pathway.

Current Evidence on Astaxanthin and Gynaecomastia

No clinical trials or regulatory bodies have established a causal link between astaxanthin and gynaecomastia; theoretical hormonal effects observed in vitro have not been replicated in human studies at standard doses.

The question of whether astaxanthin causes gynaecomastia is understandable given growing public interest in supplement safety. However, based on currently available scientific literature, there is no established or officially recognised causal link between astaxanthin supplementation and gynaecomastia.

Some concern may stem from astaxanthin's structural similarity to other carotenoids and its theoretical capacity to influence hormonal pathways. A small number of preclinical and in vitro studies have explored astaxanthin's effects on steroidogenesis — the biological process by which hormones such as oestrogen and testosterone are synthesised. Some animal studies have suggested that high-dose astaxanthin may modestly influence androgen metabolism, but these findings have not been replicated in robust human clinical trials at doses typically used in supplementation.

Astaxanthin has also been investigated in laboratory (in vitro) settings for potential 5-alpha reductase inhibitory activity — an enzyme involved in converting testosterone to dihydrotestosterone (DHT). Inhibition of this enzyme is the mechanism behind licensed medicines such as finasteride, which carry gynaecomastia as a recognised side effect. However, this effect has been observed only in laboratory conditions; there is currently no evidence that astaxanthin produces a clinically meaningful effect on this pathway in humans at standard supplementation doses.

It is also worth noting that many online reports of supplement-related side effects involve multi-ingredient products, making it difficult to attribute any effect to a single component such as astaxanthin.

At present:

• No randomised controlled trials have identified gynaecomastia as an adverse effect of astaxanthin

• No regulatory body, including the MHRA or European Medicines Agency (EMA), has issued a safety warning linking astaxanthin to gynaecomastia

• Anecdotal reports exist online but do not constitute clinical evidence

Individuals who notice breast tissue changes whilst taking astaxanthin should not assume causation, but should discuss this with their GP to rule out other causes.

When to Seek Medical Advice About Breast Tissue Changes

Any new, progressive, or painful male breast tissue change warrants GP assessment; men aged 50 or over with a unilateral firm subareolar mass should be referred urgently under NICE NG12 to exclude malignancy.

Whilst gynaecomastia is most often benign, any new or unexplained change in male breast tissue warrants medical evaluation. It is important not to dismiss such changes, particularly if they are progressive, painful, or associated with other symptoms. Consulting a GP is the appropriate first step, and this is especially important if you are currently taking any supplements, herbal products, or medications.

You should seek medical advice promptly if you notice:

• A firm or rubbery lump beneath one or both nipples

• Breast tenderness or pain that is new or worsening

• Nipple discharge of any kind

• Asymmetrical breast swelling or rapid growth of breast tissue

• Skin changes over the breast, such as dimpling, redness, or ulceration

• Symptoms alongside unexplained weight loss, fatigue, or testicular changes

In line with NICE NG12 guidance, men aged 50 or over with a unilateral, firm subareolar mass — with or without nipple retraction or discharge — should be referred urgently via the 2-week-wait pathway to exclude breast malignancy. If you have any of these features, ask your GP about urgent referral.

Your GP will typically take a full medical and medication history — including any supplements you are taking — and perform a physical examination, including testicular examination where clinically indicated. Depending on findings, they may arrange blood tests to assess hormone levels, including oestradiol (E2), LH, FSH, and prolactin, as well as liver function, renal function, and thyroid function tests. Where a testicular or germ-cell tumour is suspected, beta-hCG (β-hCG) should also be measured. In some cases, referral for breast ultrasound or to an endocrinologist or breast clinic may be appropriate (NICE CKS: Gynaecomastia).

If you are taking astaxanthin or any other supplement and develop breast tissue changes, it is sensible to stop the supplement temporarily and inform your GP, even if a causal link seems unlikely. This allows for a clearer clinical picture and ensures that all potential contributing factors are considered. Do not stop any prescribed medication without first consulting your doctor.

Reporting Supplement Side Effects via the MHRA Yellow Card Scheme

Suspected adverse reactions to supplements, including breast tissue changes, should be reported to the MHRA via the Yellow Card scheme online, by app, or through a healthcare professional — suspicion alone is sufficient to report.

Experiencing these side effects? Our pharmacists can help you navigate them →

In the UK, the MHRA operates the Yellow Card scheme — a pharmacovigilance system that allows both healthcare professionals and members of the public to report suspected adverse reactions to medicines, vaccines, and, importantly, herbal or dietary supplements. This scheme plays a vital role in identifying safety signals that may not have been apparent during pre-market evaluation, particularly for products such as food supplements that undergo less rigorous pre-licensing scrutiny.

If you believe that astaxanthin or any other supplement has caused or contributed to a side effect — including unexpected breast tissue changes — you are encouraged to submit a report via the Yellow Card scheme. Reports can be submitted:

• Online at the MHRA Yellow Card website (yellowcard.mhra.gov.uk)

• Via the Yellow Card app, available on iOS and Android

• Through your GP, pharmacist, or other healthcare professional

You do not need to be certain that the supplement caused the reaction — suspicion alone is sufficient grounds for reporting. The MHRA uses aggregated data from Yellow Card reports to identify patterns and, where necessary, take regulatory action or issue public safety communications.

Healthcare professionals are also encouraged to report suspected supplement-related adverse effects, as professional reports carry particular weight in pharmacovigilance assessments. Increased reporting of supplement-related concerns helps build a more complete evidence base, ultimately improving patient safety across the UK.

In summary, whilst current evidence does not support a direct link between astaxanthin and gynaecomastia, any concerning physical changes should be assessed medically, and suspected supplement reactions should be reported through the appropriate channels. Informed, cautious use of supplements — combined with open communication with healthcare providers — remains the safest approach.

Frequently Asked Questions